{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=41", "query": { "intervention": "Combination 400", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T00:39:59.821Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01596751", "title": "Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hope Rugo, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-07-12", "completion_date": "2019-07-05", "has_results": true, "last_update_posted_date": "2020-07-17", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 3, "location_summary": "San Francisco, California • Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596751" }, { "nct_id": "NCT01332227", "title": "Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV, Combination Therapy" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir (heat-stable)", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2011-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332227" }, { "nct_id": "NCT02781649", "title": "Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End-Stage Renal Disease", "Hepatitis C" ], "interventions": [ { "name": "Zepatier", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 10, "start_date": "2016-07-20", "completion_date": "2018-01-01", "has_results": true, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02781649" }, { "nct_id": "NCT03212989", "title": "Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "HXTC", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 17, "start_date": "2017-06-27", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03212989" }, { "nct_id": "NCT03822468", "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 376, "start_date": "2019-06-11", "completion_date": "2024-08-30", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 14, "location_summary": "Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822468" }, { "nct_id": "NCT01448044", "title": "Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BMS-790052 (NS5A Replication Complex Inhibitor)", "type": "DRUG" }, { "name": "Placebo matching BMS-790052", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2011-12", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 4, "location_summary": "San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more", "locations": [ { "city": "San Clemente", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448044" }, { "nct_id": "NCT04929223", "title": "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "SY-5609", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FoundationOne®Liquid CDx", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2021-10-22", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929223" }, { "nct_id": "NCT00599924", "title": "Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Neoplasms" ], "interventions": [ { "name": "sunitinib + FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2005-09", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2015-07-15", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 3, "location_summary": "Aurora, Colorado • Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00599924" }, { "nct_id": "NCT05609370", "title": "A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer" ], "interventions": [ { "name": "Alcestobart", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab or Bevacizumab biosimilar", "type": "DRUG" }, { "name": "Fluoropyrimidine (FP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2023-01-29", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609370" }, { "nct_id": "NCT06896188", "title": "9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-09-22", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-11T00:39:59.821Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06896188" } ] }